Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Update

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 4,820,000 shares, an increase of 8.6% from the December 31st total of 4,440,000 shares. Currently, 19.6% of the company’s stock are short sold. Based on an average daily volume of 400,900 shares, the short-interest ratio is currently 12.0 days.

Arcturus Therapeutics Price Performance

ARCT stock opened at $15.80 on Tuesday. Arcturus Therapeutics has a 52-week low of $14.30 and a 52-week high of $45.00. The stock has a market capitalization of $428.02 million, a price-to-earnings ratio of -7.12 and a beta of 2.62. The company has a 50-day moving average of $17.27 and a two-hundred day moving average of $19.41.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $41.67 million for the quarter, compared to analysts’ expectations of $49.16 million. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. Equities analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Analyst Ratings Changes

ARCT has been the topic of a number of analyst reports. BTIG Research started coverage on Arcturus Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $41.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $61.60.

Institutional Trading of Arcturus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Empire Life Investments Inc. grew its holdings in Arcturus Therapeutics by 85.5% during the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock valued at $4,742,000 after purchasing an additional 128,771 shares during the period. Spire Wealth Management lifted its holdings in Arcturus Therapeutics by 393.3% during the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 10,746 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after acquiring an additional 3,705 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Arcturus Therapeutics by 139.7% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company’s stock worth $1,393,000 after purchasing an additional 47,824 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in shares of Arcturus Therapeutics by 3.7% during the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company’s stock valued at $1,097,000 after purchasing an additional 2,335 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.